Hi Avinash (Jonah and Ni are cc:ed for confirmation),
I believe for the patient part of covid19cellatlas you should reference this preprint:
https://www.medrxiv.org/content/10.1101/2020.11.20.20227355v1
And for the healthy part of the atlas you should reference this article:
https://www.nature.com/articles/s41591-020-0868-6
Hope this helps,
Cheers,
Vlad
--
Vladimir Kiselev
CellGen
Informatics<http://www.sanger.ac.uk/science/groups/cellular-genetics-informatics>
Team Leader
Wellcome Sanger Institute
Wellcome Genome Campus
Hinxton, Cambridge, CB10 1SA
Phone: +44 (0) 1223 496850
Message: Mattermost<https://mattermost.sanger.ac.uk/cellgeninf> or
Slack<https://cellgeni.slack.com/>
Web:
https://wikiselev.github.io
From: Avinash Sahu <asahu(a)ds.dfci.harvard.edu>
Date: Monday, 14 December 2020 at 10:07
To: "cv19caingest(a)sanger.ac.uk" <cv19caingest(a)sanger.ac.uk>
Subject: [Cv19caingest] CV19 cell atlas publication policy [EXT]
Dear all,
We, computational scientists, are developing new statistical methods for the analysis of
single-cell data. The application of these methods to COVID-19 data has revealed novel
findings in terms of its biology, which would also impact its treatment. We are gearing
towards the submission of these findings. Could you let us know regarding the policy of
publication manuscripts that leverage COVID19 cell atlas data? We will be happy to
accommodate researchers who had generated the data as co-authors in the manuscript as
deemed necessary.
Avinash Sahu
Research Fellow
asahu@ds.dfci.harvard.edu<mailto:asahu@ds.dfci.harvard.edu>
https://connects.catalyst.harvard.edu/Profiles/display/Person/165880
[
connects.catalyst.harvard.edu]<https://urldefense.proofpoint.com/v2/url?…
[cid:B4ECB6A7-EF48-40BA-8237-29F0067204FA]